Our protocol was optimized for the immunoaffinity purification of CUZD1 from as little as 20–100 μg of pancreatic lysate using anti-CUZD1 autoantibodies present in 2.5–25 μl of IBD patient sera. Here, CUZD1 is linked to inflammatory bowel disease.